Clin2
NCT07682675Possibly a fitNot yet recruiting

Testing zanzalintinib for advanced head and neck cancer

Adenoid Cystic Carcinoma of the Salivary GlandRecurrenceMetastatic Disease

Treatments studied

Part of Cancer clinical trials.

This trial studies an experimental drug called zanzalintinib for people with adenoid cystic carcinoma that has spread or come back. The goal is to see if the drug can shrink tumors or slow the disease.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 2
Enrollment
51 people
Ages
18 years and older
Study type
Interventional

Who can take part

  • You are 18 years or older.
  • You have adenoid cystic carcinoma in the head or neck that has spread or cannot be removed with surgery.
  • Your cancer has gotten significantly worse in the last 3 months, shown by scans.
  • You are able to have a biopsy of your tumor before starting treatment.
  • Your overall health is good (able to do daily activities without help).
  • You have not taken certain other cancer treatments within the past 2 to 4 weeks.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06912087Recruiting· Phase 1
Finding the right dose of a new combo for head and neck cancer

This trial tests a new three-drug combination for advanced head and neck cancer that cannot be cured by local treatments. It aims to find the best dose of a targeted therapy called Zanzalintinib when given with two standard immunotherapy and targeted drugs.

Chicago, Illinois
NCT07193550Recruiting· Phase 2
Testing Zanzalintinib for Advanced Bone Sarcomas

This trial tests a new drug called zanzalintinib for people with advanced or metastatic bone sarcomas that have not responded to standard treatments. It aims to see if the drug can help shrink or slow the growth of these tumors.

Houston, Texas
NCT07042919Recruiting· Phase 1/Phase 2
Zanzalintinib for advanced liver cancer after prior treatment

This trial tests a new drug called zanzalintinib for people with advanced liver cancer (HCC) that can't be treated with surgery. You may join if your cancer has gotten worse after at least one prior treatment, or you couldn't tolerate that treatment.

Chicago, Illinois
NCT07714551Not yet recruiting· Phase 2
Testing zanzalintinib for progressive pheochromocytoma or paraganglioma

This trial tests an oral drug called zanzalintinib in people with pheochromocytoma or paraganglioma that has spread or cannot be removed by surgery and has gotten worse. The goal is to see if the drug can slow or stop tumor growth.

Boston, Massachusetts
NCT07185945Not yet recruiting· Phase 2
Zanzalintinib for advanced bladder cancer after prior therapy

This trial tests a new drug called zanzalintinib for people with advanced bladder cancer that has worsened after previous treatments. The goal is to see if zanzalintinib can help control the cancer.

NCT06959511Recruiting· Phase 2
Zanzalintinib for advanced thyroid cancer before surgery

This trial tests a drug called zanzalintinib for people with advanced thyroid cancer that has spread nearby. The goal is to see if taking this pill before surgery can shrink the tumor and make it easier to remove.

Ann Arbor, Michigan

Hear when a new Adenoid Cystic Carcinoma of the Salivary Gland trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.